Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib

BACKGROUND: Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavric, Ana Ursula, Ocvirk, Janja, Mekjavic, Polona Jaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043881/
https://www.ncbi.nlm.nih.gov/pubmed/30018526
http://dx.doi.org/10.2478/raon-2018-0002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043881/
https://www.ncbi.nlm.nih.gov/pubmed/30018526
http://dx.doi.org/10.2478/raon-2018-0002

Ejemplares similares